Hansa Medical Interim report July – September 2018
July – September 2018 in brief ›› Hansa successfully completed two Phase 2 clinical studies evaluating imlifidase for kidney transplantation in highly sensitized patients, with imlifidase enabling transplantation in all 35 patients. ›› Imlifidase met all primary and secondary endpoints in each study. ›› Treatment with imlifidase enabled highly sensitized patients to receive life-saving transplants. ›› Hansa plans to submit Biologics License Application (BLA) and Marketing Authorization Application (MAA) filings by Q1 2019, with their potential acceptance of submission within 60